BiotechTube
Home/EndoLipiD Therapeutics/David M. Selva, PhD
DM

David M. Selva, PhD

CSO, Board Member

EndoLipiD Therapeutics

Therapeutic Areas

MetabolicCardiovascularAesthetic

EndoLipiD Therapeutics Pipeline

DrugIndicationPhase
EDL6DNASH (Non-alcoholic steatohepatitis)Preclinical
EDL81 (Ac-EDL67)CellulitePreclinical

Leadership Team at EndoLipiD Therapeutics

GD
Giacomo de Simone, PhD
CEO
RS
Rafael Simó, MD, Prof
CMO
AS
Agustí Soler
CFO
View full EndoLipiD Therapeutics profile